balertatug   Click here for help

GtoPdb Ligand ID: 13800

Immunopharmacology Ligand
Compound class: Antibody
Comment: Balertatug is the INN for an anti-CD70 monoclonal antibody. Peptide sequence matches this to claims in patent US8067546B2; Humanized anti-CD70 binding agents and uses thereof [1]. May align with SeaGen's clinical candidate SGN-70/SEA-CD70 that was developed for antitumour activity against CD70-positive cancers (principally myelodysplastic syndrome and acute myeloid leukemia) [2]. The antibody blocks activation of the CD70/CD27 signalling pathway that promotes stemness and proliferation of leukemic blasts. It is engineered to enhance effector functions; antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). Internal company identifier was switched to PF-08046040 when Pfizer acquired SeaGen.
No information available.
Summary of Clinical Use Click here for help
PF-08046040 is a clinical candidate for myelodysplastic syndrome and acute myeloid leukemia.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04227847 A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies Phase 1 Interventional Seagen Inc. The SGNS70-101 study.